Blog

[printfriendly]
  • Oct 1, 2011

    KRN5500 Demonstrated Significant Decrease in the Intensity of Neuropathic Pain in Patients with Cancer

    DARA BioSciences, recently awarded fast track designation from the FDA for the development of their new drug for the treatment of neuropathic pain, has just released the results of a…
  • Oct 1, 2011

    Cancer Patients Could Benefit from Greater Use of Rehabilitation

    Kaiser Health just release information about studies which indicate that rehabilitation for cancer patients, during and after chemotherapy treatments, are necessary to regain enough functionality to perform ordinary activities. One…
  • Oct 1, 2011

    Cancer Researchers Study 'Scrambler Therapy' for Pain Relief

    Researchers at University of Wisconsin Carbone Cancer Center are testing a new pain therapy device for patients with nerve pain following chemotherapy treatments. With 40 percent of chemotherapy patients developing…
  • Oct 1, 2011

    Colorectal Cancer Drug Linked with Nerve Damage

    Oxaliplatin has become the standard of care for people with advanced colorectal cancer. It appears to cause nerve damage that may be permanent and worsens even months after treatment ends….
  • Sep 20, 2011

    New Research has Potential to Alleviate Side Effects of Cancer Treatments

    Beth Faiman MSN, CNP, a doctoral candidate at the Frances Payne Bolton School of Nursing at Case Western Reserve University, is studying whether an over-the-counter medication could ease chemotherapy side effects…
  • Sep 12, 2011

    Westover Vets Fight for Agent Orange Benefits

    An Air Force reserve squadron out of Westover Air Force Base in Massachusetts, is finding some curious coincidences among the men who served with them. C-123 Provider planes used to…
  • Sep 1, 2011

    Scientists Find Gene that Controls Chronic Pain

    Scientists at Cambridge University, London, have identified a gene responsible for regulating chronic pain. Their drug discovery should help drug researchers in their search for more effective, targeted pain-killing medicines….
  • Sep 1, 2011

    NeurogesX Submits Supplemental new Drug Application for Qutenza (R) 8% Patch for HIV-Associated Peripheral Neuropathy

    Biopharmaceutical company, NeurogesX, announced it submitted a supplemental new drug to the US FDA seeking to expand the label to include an application for the management of pain due to…